VALENCIA, Spain & BOSTON--(BUSINESS WIRE)--Polypeptide Therapeutic Solutions (PTS), a leader in the design, development, and custom manufacturing of polyamino-acid based delivery systems for vaccines and therapeutics, today announced the company has changed its name to Curapath. As part of Curapath’s transformation, the company has expanded existing capabilities in development and production of novel functional lipid and polymer excipients and nanoparticle formulations.
VALENCIA, Spain & BOSTON--(BUSINESS WIRE)--Polypeptide Therapeutic Solutions (PTS), a leader in the design, development and custom manufacturing of polyamino-acid based delivery systems for therapeutic drugs today announced the appointment of Robert Shaw as Chief Executive Officer.
CARLSBAD, Calif., Sept. 21, 2021 /PRNewswire/ -- Amicrobe, Inc., designs and develops breakthrough biologics at the interface of materials science and biotechnology. Called Amicidins, these synthetic proteins are made for local application to exposed tissues, such as those found in surgical and traumatic wounds. To produce clinical-grade Amicidins, Amicrobe selected contract manufacturer Polypeptide Therapeutic Solutions (PTS), a global leader in amino acid polymer synthesis and characterization. In a successful collaboration, Amicrobe's lead biologics, Amicidin-? and Amicidin-?, were produced at kilogram-scale under Good Manufacturing Practice (GMP) guidelines. The Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator (CARB-X) has funded the development of Amicidin-? since 2017.
ZURICH (Reuters) - PolyPeptide Group, controlled by a foundation of Swedish billionaire adventurer Frederik Paulsen Jr., said Monday it plans to list a 40% stake on the Swiss stock exchange to finance the contract drug maker’s growth.
In Spain, private capital increases and venture capital are consolidated as the main financing instruments for the biotechnology sector.
Polypeptide Therapeutic Solutions, S.L. ha desarrollado con éxito entre 2017 y 2020 dos proyectos denominados “IMPLANTACIÓN DE NUEVAS TECNOLOGÍAS ORIENTADAS A LA OBTENCIÓN, CONTROL Y GESTIÓN DE DATOS ANALÍTICOS” y “IMPLANTACIÓN DE UN NUEVO ERP IN CLOUD PARA LA GESTIÓN DE DIFERENTES ÁREAS DE LA EMPRESA DE FORMA CENTRALIZADA”, para los que ha contado con el apoyo IVACE y FEDER, a través de su programa de apoyo a “PROYECTOS DE DIGITALIZACIÓN DE PYME (DIGITALIZA-CV)” en las convocatorias 2017 y 2018, respectivamente.
The main aim of the project BIOMOLMACS is to establish a multidisciplinary training network on the emerging topic of molecular machines. In the last decades, great efforts have been spent on the development of synthetic strategies for the creation of molecular machines, and these efforts have been acknowledged by the Nobel committee in 2016. The next important step is to incorporate the molecular machines in devices with application potential. For this purpose, the machines will be integrated in mesoscopic assemblies by employing well-defined polymeric components with structural and functional control. Sequence controlled polymers open up greater possibilities in the precise formation of nanoparticles such as polymersomes, and even support the generation of artificial cells. The combined molecular toolbox of molecular machines and precisely designed synthetic macromolecules will support the design of devices with innovative nanomedical application potential. 15 Early Stage Researchers will be trained on the design, synthesis, and characterization of such complex (macro)molecular building blocks, their subsequent devices, as well as their utilization in artificial and living cells. Besides, biophysical understanding of molecular interactions in living/synthetic systems will bridge the gap between fundamental and applied research.
PTS is a company devoted to the design and manufacture of polypeptide-based materials for drug delivery and high-tech applications. With more than 30 years of experience in polypeptide & materials science, drug delivery, custom manufacturing, analytical characterization and quality assurance we are committed to one purpose, your success.
Cette analyse de marché crée une étude approfondie des prévisions sur le Marché Chloroformiate de cyclopentyle Mondial, elle fournit des informations détaillées sur l’évolution du marché Chloroformiate de cyclopentyle dans le passé récent et offre des informations précieuses sur l’avenir proche. Le Rapport sur le marché Chloroformiate de cyclopentyle propose l’analyse objective de Chloroformiate de cyclopentyle en tant que facteur émergent sur le marché mondial. Tous les facteurs propices au marché Chloroformiate de cyclopentyle ont été analysés dans le rapport. La vue d’ensemble du marché mondial de Chloroformiate de cyclopentyle a été présentée sous forme d’étude et les développements concernant l’exploitation hôtelière ont été classés en fonction des perspectives d’avenir.